Last updated on April 2019

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations


Other Details:

For more information, please contact Incyte Corporation at 1.855.463.3463



Find a site near you

Start Over

Florida Hospital Cancer Institute

Located in: Orlando, FL USA
8.34miles
  Connect »